- Home
- FLC vs ACRV Comparison
FLC vs ACRV Comparison
Compare FLC & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- ACRV
- Stock Information
- Founded
- FLC 2003
- ACRV 2018
- Country
- FLC United States
- ACRV United States
- Employees
- FLC N/A
- ACRV N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- FLC Finance
- ACRV Health Care
- Exchange
- FLC Nasdaq
- ACRV Nasdaq
- Market Cap
- FLC 176.2M
- ACRV 170.3M
- IPO Year
- FLC N/A
- ACRV 2022
- Fundamental
- Price
- FLC $16.85
- ACRV $5.78
- Analyst Decision
- FLC
- ACRV Strong Buy
- Analyst Count
- FLC 0
- ACRV 5
- Target Price
- FLC N/A
- ACRV $22.40
- AVG Volume (30 Days)
- FLC 37.8K
- ACRV 52.8K
- Earning Date
- FLC 01-01-0001
- ACRV 11-13-2024
- Dividend Yield
- FLC 6.64%
- ACRV N/A
- EPS Growth
- FLC N/A
- ACRV N/A
- EPS
- FLC N/A
- ACRV N/A
- Revenue
- FLC N/A
- ACRV N/A
- Revenue This Year
- FLC N/A
- ACRV N/A
- Revenue Next Year
- FLC N/A
- ACRV N/A
- P/E Ratio
- FLC N/A
- ACRV N/A
- Revenue Growth
- FLC N/A
- ACRV N/A
- 52 Week Low
- FLC $12.62
- ACRV $3.19
- 52 Week High
- FLC $15.45
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- FLC 55.43
- ACRV 43.36
- Support Level
- FLC $16.46
- ACRV $5.36
- Resistance Level
- FLC $16.89
- ACRV $6.00
- Average True Range (ATR)
- FLC 0.23
- ACRV 0.54
- MACD
- FLC 0.02
- ACRV -0.02
- Stochastic Oscillator
- FLC 74.58
- ACRV 24.73
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.